Danaher Schedules Fourth Quarter 2025 Earnings Conference Call
Rhea-AI Summary
Danaher (NYSE: DHR) will webcast its Fourth Quarter 2025 earnings conference call on Wednesday, January 28, 2026 at 8:00 a.m. ET, with an expected duration of about one hour.
The company will discuss financial performance and future expectations. The live webcast and accompanying slide presentation will be available in the Investors > Events & Presentations section at www.danaher.com. Webcast slides, the earnings press release, and related materials will be posted beginning at 6:00 a.m. ET on the day of the call.
Dial-in access: 800-245-3047 (U.S.) or +1 203-518-9765 (outside U.S.); Conference ID: DHRQ425. A replay of the webcast and call will be available after the presentation; the call replay remains available until February 11, 2026.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, DHR declined 0.92%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While DHR was down 1.68%, key diagnostics and tools peers like TMO (-0.12%), A (-0.93%), IDXX (-0.62%), LH (-2.08%), and MTD (-2.00%) also showed mild declines, but no momentum-cluster signal appeared.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Dividend declaration | Positive | +3.2% | Announced regular cash dividend of $0.32 per share with set pay date. |
| Nov 11 | Conference presentation | Positive | +1.7% | CEO presentation at Jefferies healthcare conference with live webcast access. |
| Oct 21 | Quarterly earnings | Positive | +5.9% | Q3 2025 results with revenue, EPS growth and maintained full-year guidance. |
| Sep 23 | Earnings call schedule | Neutral | -2.0% | Scheduled Q3 2025 earnings call with webcast and replay details. |
| Sep 10 | Clinical technology | Positive | -0.9% | Launch of automated BD-Tau RUO immunoassay advancing neurodegenerative research. |
Recent news with clear fundamentals (earnings, dividend) tended to see positive price alignment, while clinical and scheduling updates showed more mixed or divergent reactions.
Over the last few months, Danaher’s news flow has combined capital returns, earnings delivery, and operational innovation. A $0.32 quarterly dividend announcement on Dec 09 coincided with a +3.22% move. Q3 2025 results on Oct 21 highlighted $6.1B revenue and solid cash generation, with shares up 5.94%. By contrast, scheduling notices for earnings calls, like the Q3 call set on Sep 23, and clinical innovation updates such as the BD‑Tau assay launch on Sep 10, saw modest or negative reactions, underscoring investor focus on concrete financial outcomes.
Market Pulse Summary
This announcement sets the timetable for Danaher’s Q4 2025 earnings discussion on January 28, 2026 at 8:00 a.m. ET, with materials posted from 6:00 a.m. ET and replay access through February 11, 2026. It continues the company’s regular cadence of quarterly calls, where management reviews financial performance and expectations. Investors may look back to recent Q3 2025 results and dividend actions as context, and will likely focus on updated revenue, EPS, and guidance details once the full release is issued.
AI-generated analysis. Not financial advice.
The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.
You can access the conference call by dialing 800-245-3047, within the
Danaher's earnings press release, the webcast slides and other related materials will be posted to the "Investors" section of Danaher's website under the subheading "Quarterly Earnings" beginning at 6:00 a.m. ET on the date of the earnings call and will remain available following the call.
ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
View original content:https://www.prnewswire.com/news-releases/danaher-schedules-fourth-quarter-2025-earnings-conference-call-302644315.html
SOURCE Danaher Corporation
FAQ
When will Danaher (DHR) hold its Q4 2025 earnings call?
How can investors access Danaher (DHR) Q4 2025 webcast and slides?
What are the dial-in numbers and conference ID for Danaher (DHR) Q4 2025 call?
When will Danaher (DHR) post the earnings press release and presentation slides?
How long will the replay of Danaher (DHR) Q4 2025 conference call be available?
Where can I find the replay dial-in information for Danaher (DHR) Q4 2025 call?
